Literature DB >> 21803776

The extracellular cAMP-adenosine pathway regulates expression of renal D1 dopamine receptors in diabetic rats.

Eldo V Kuzhikandathil1, Leslie Clark, Ying Li.   

Abstract

Activation of D1 dopamine receptors expressed in the kidneys promotes the excretion of sodium and regulates sodium levels during increases in dietary sodium intake. A decrease in the expression or function of D1 receptors results in increased sodium retention which can potentially lead to the development of hypertension. Studies have shown that in the absence of functional D1 receptors, in null mice, the systolic, diastolic, and mean arterial pressures are higher. Previous studies have shown that the expression and function of D1 receptors in the kidneys are decreased in animal models of diabetes. The mechanisms that down-regulate the expression of renal D1 receptor gene in diabetes are not well understood. Using primary renal cells and acutely isolated kidneys from the streptozotocin-induced rat diabetic model, we demonstrate that the renal D1 receptor expression is down-regulated by the extracellular cAMP-adenosine pathway in vitro and in vivo. In cultures of primary renal cells, a 3 mm, 60-h cAMP treatment down-regulated the expression of D1 receptors. In vivo, we determined that the plasma and urine cAMP levels as well as the expression of 5'-ectonucleotidase, tissue-nonspecific alkaline phosphatase, and adenosine A2a receptors are significantly increased in diabetic rats. Inhibitors of 5'-ectonucleotidase and tissue-nonspecific alkaline phosphatase, α,β-methyleneadenosine 5'-diphosphate, and levamisole, respectively, blocked the down-regulation of D1 receptors in the primary renal cells and in the kidney of diabetic animals. The results suggest that inhibitors of the extracellular cAMP-adenosine pathway reverse the down-regulation of renal D1 receptor in diabetes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21803776      PMCID: PMC3173236          DOI: 10.1074/jbc.M111.268136

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

1.  EFFECT OF DOPAMINE IN MAN: AUGMENTATION OF SODIUM EXCRETION, GLOMERULAR FILTRATION RATE, AND RENAL PLASMA FLOW.

Authors:  R H MCDONALD; L I GOLDBERG; J L MCNAY; E P TUTTLE
Journal:  J Clin Invest       Date:  1964-06       Impact factor: 14.808

2.  THE EFFECT OF L-EPINEPHRINE AND OTHER AGENTS ON THE SYNTHESIS AND RELEASE OF ADENOSINE 3',5'-PHOSPHATE BY WHOLE PIGEON ERYTHROCYTES.

Authors:  P R DAVOREN; E W SUTHERLAND
Journal:  J Biol Chem       Date:  1963-09       Impact factor: 5.157

3.  Extracellular nucleotide signaling in adult neural stem cells: synergism with growth factor-mediated cellular proliferation.

Authors:  Santosh K Mishra; Norbert Braun; Varsha Shukla; Marc Füllgrabe; Christof Schomerus; Horst-Werner Korf; Christian Gachet; Yukio Ikehara; Jean Sévigny; Simon C Robson; Herbert Zimmermann
Journal:  Development       Date:  2006-02       Impact factor: 6.868

Review 4.  Dopamine receptors: from structure to function.

Authors:  C Missale; S R Nash; S W Robinson; M Jaber; M G Caron
Journal:  Physiol Rev       Date:  1998-01       Impact factor: 37.312

5.  Immunolocalization of ectonucleotidases along the rat nephron.

Authors:  Renu M Vekaria; David G Shirley; Jean Sévigny; Robert J Unwin
Journal:  Am J Physiol Renal Physiol       Date:  2005-09-27

6.  Immunolocalization of tissue non-specific alkaline phosphatase in mice.

Authors:  K Hoshi; N Amizuka; K Oda; Y Ikehara; H Ozawa
Journal:  Histochem Cell Biol       Date:  1997-03       Impact factor: 4.304

7.  Region-specific alterations of adenosine receptors expression level in kidney of diabetic rat.

Authors:  Tadeusz Pawelczyk; Marzena Grden; Robert Rzepko; Monika Sakowicz; Andrzej Szutowicz
Journal:  Am J Pathol       Date:  2005-08       Impact factor: 4.307

8.  Does conversion of ATP to adenosine terminate ATP-stimulated vasopressin release from hypothalamo-neurohypophyseal explants?

Authors:  Zhilin Song; Celia D Sladek
Journal:  Brain Res       Date:  2005-06-14       Impact factor: 3.252

9.  Immunotherapeutic effects of mangiferin mediated by the inhibition of oxidative stress to activated lymphocytes, neutrophils and macrophages.

Authors:  S Muruganandan; J Lal; P K Gupta
Journal:  Toxicology       Date:  2005-08-01       Impact factor: 4.221

Review 10.  Animal models for the study of adenosine receptor function.

Authors:  R Yaar; M R Jones; J-F Chen; Katya Ravid
Journal:  J Cell Physiol       Date:  2005-01       Impact factor: 6.384

View more
  6 in total

Review 1.  The 2',3'-cAMP-adenosine pathway.

Authors:  Edwin K Jackson
Journal:  Am J Physiol Renal Physiol       Date:  2011-09-21

Review 2.  Renal dopaminergic system: Pathophysiological implications and clinical perspectives.

Authors:  Marcelo Roberto Choi; Nicolás Martín Kouyoumdzian; Natalia Lucía Rukavina Mikusic; María Cecilia Kravetz; María Inés Rosón; Martín Rodríguez Fermepin; Belisario Enrique Fernández
Journal:  World J Nephrol       Date:  2015-05-06

Review 3.  Purines: forgotten mediators in traumatic brain injury.

Authors:  Edwin K Jackson; Detlev Boison; Michael A Schwarzschild; Patrick M Kochanek
Journal:  J Neurochem       Date:  2016-02-25       Impact factor: 5.372

Review 4.  Dopamine Receptors and the Kidney: An Overview of Health- and Pharmacological-Targeted Implications.

Authors:  Alejandro Olivares-Hernández; Luis Figuero-Pérez; Juan Jesus Cruz-Hernandez; Rogelio González Sarmiento; Ricardo Usategui-Martin; José Pablo Miramontes-González
Journal:  Biomolecules       Date:  2021-02-10

5.  Interactive roles of CD73 and tissue nonspecific alkaline phosphatase in the renal vascular metabolism of 5'-AMP.

Authors:  Edwin K Jackson; Dongmei Cheng; Jonathan D Verrier; Keri Janesko-Feldman; Patrick M Kochanek
Journal:  Am J Physiol Renal Physiol       Date:  2014-07-02

6.  Cyclic nucleotide permeability through unopposed connexin hemichannels.

Authors:  Virginijus Valiunas
Journal:  Front Pharmacol       Date:  2013-06-06       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.